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Ventilator-associated pneumonia (VAP) is defined as
nosocomial pneumonia in a patient on mechanical ventilatory
support (by endotracheal tube or tracheostomy) for >48 hours.
For many years, VAP has been diagnosed by the clinical
criteria published by Johanson et al. in 1972, which include
the appearance of a new or progressive pulmonary infiltrate,
fever, leukocytosis, and purulent tracheobronchial secretions
(1); however, these criteria are nonspecific (2). In the
mechanically ventilated patient, fever may be caused by a
drug reaction, extrapulmonary infection, blood transfusion,
or extrapulmonary inflammation. Pulmonary infiltrates may
be due to pulmonary hemorrhage, chemical aspiration,
pleural effusion, congestive heart failure, or tumor. Both fever
and pulmonary infiltrates occur in the fibroproliferation of
late acute respiratory distress syndrome, atelectasis, and
pulmonary embolism, as well as in VAP. Cultures of tracheal
aspirates are not very useful in establishing the cause of VAP
(2). Although such cultures are highly sensitive, their specificity
is low even when they are cultured quantitatively (3).
VAP can be accurately diagnosed by any one of several
standard criteria: histopathologic examination of lung tissue
obtained by open lung biopsy, rapid cavitation of a pulmonary
infiltrate in the absence of cancer or tuberculosis, positive
pleural fluid culture, same species with same antibiogram
isolated from blood and respiratory secretions without
another identifiable source of bacteremia, and histopatho-
logic examination of lung tissue at autopsy (4). However,
these criteria are based on invasive procedures for obtaining
lung tissue or on uncommon manifestations or complications
of VAP. Given the invasive nature of lung biopsy and the
infrequent occurrence of other manifestations used as
standard criteria, another approach is needed for the
definitive diagnosis of VAP. In 1979, a fiberoptic
bronchoscopic technique was introduced for obtaining
uncontaminated lower respiratory tract secretions, which
were cultured quantitatively (5). The causative microorgan-
isms were recovered at >103 CFU/mL from six patients with
clinical evidence of lower respiratory tract infection.
In 1987, a correlation was observed between pneumonia
and >105 CFU/mL in bronchoalveolar lavage (BAL) fluid (6,7).
Kahn and Jones noted that BAL fluid with >105 CFU/mL and
<1% squamous epithelial cells had 100% sensitivity and
specificity for the diagnosis of bacterial pneumonia.
Two bronchoscopic techniques have been introduced for
the accurate diagnosis of VAP in the absence of standard
criteria. The protected specimen brush (PSB) collects 0.001
mL of lower respiratory tract secretions and has a diagnostic
threshold of >103 CFU/mL (8). BAL, an unprotected
technique, samples approximately one million alveoli and has
a diagnostic threshold of >104 CFU/mL (8). A protected BAL
technique with a balloon-tipped catheter has also been
described (9). Detection of >5% of neutrophils or macrophages
with intracellular organisms on a Wright-Giemsa stain of a
smear of cytocentrifuged BAL fluid is also diagnostic of VAP
(10).
Bronchoscopically Directed
Techniques for Diagnosis of VAP
The accuracy of quantitative culture and microscopic
examination of lower respiratory tract secretions for the
diagnosis of VAP was validated by Chastre et al. (10,11), who
compared the results of quantitatively cultured lower
respiratory tract secretions with those of culture and
histopathologic examination of simultaneously obtained lung
tissue. In the first study, quantitative culture of secretions
obtained by PSB was compared with histopathologic
examination and quantitative culture of lung tissue (11). Of
six patients with pneumonia confirmed by histologic criteria,
all had at least one microorganism obtained at a
concentration of >104 CFU/g of lung tissue. Compared with
the results of histologic examination and quantitative culture
of lung tissue, quantitative culture of secretions obtained by
PSB using a diagnostic threshold of >103 CFU/mL had a
sensitivity of 100%, specificity of 60%, positive predictive
value of 43%, and negative predictive value of 100%.
In the second study, the results of PSB, BAL, and >5%
intracellular organisms were compared with simultaneously
obtained lung tissue (Table) (10). Patients were included in
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the study only if they had never had pneumonia or had
acquired it during the terminal phase of their illness.
Bronchoscopy was performed within 1 hour after death, while
mechanical ventilation was continued and PSB and BAL
samples were taken. Immediately after bronchoscopy, a left
thoracotomy was performed, and lung tissue specimens were
taken from the areas of lung where the bronchoscopic samples
had been obtained. All but two patients had been receiving
antibiotics before death, but antibiotic therapy had not been
changed for >3 days. All lung segments judged to have
moderate to severe pneumonia by histologic criteria yielded
>104 CFU/g of tissue.
Four other published studies have concluded that
bronchoscopically directed techniques were not more accurate
for diagnosis of VAP than clinical and X-ray criteria combined
with cultures of tracheal aspirates (12-15). In one study,
quantitative cultures of lower respiratory tract secretions
obtained by PSB and BAL were compared with quantitative
culture and histopathologic examination of lung tissue taken
from the same areas sampled by PSB and BAL (12). These
investigators used >103 CFU/g of lung tissue as a threshold
for positive cultures of lung tissue; in addition, patients were
enrolled at any time during mechanical ventilation, so that
pulmonary infiltrates could have been included from earlier
pneumonia or current pneumonia with bacteria previously
eradicated from some foci and still present in other areas of
the lung. When multiple inflammatory foci of varying ages are
present in the lungs, histopathologic examination and culture
of lung tissue may not correlate with results of quantitative
cultures of simultaneously obtained lower respiratory tract
secretions.
Other investigators compared the results of quantitative
culture and microscopic examination of lower respiratory
tract secretions obtained by PSB and BAL with histopatho-
logic examination of lungs at autopsy performed within 3 days
of bronchoscopic sampling of the lower airways (13).
Specificity and positive predictive values for cultures of
secretions collected by PSB and BAL were comparable with
those observed by Chastre et al. (10,11); however,
substantially lower sensitivities of 57.8% and 47.3% and
negative predictive values of 51% and 48% were observed for
PSB and BAL, respectively. These discrepant findings may be
due to the study design, in which sampling of lower airways
and examination of lung tissue were separated by up to 3
days, the areas from which PSB and BAL samples were taken
could not be precisely matched with the same areas examined
histopathologically, and lung tissue could not be cultured
because lungs were examined at autopsy.
In a comparative study, quantitative culture and
microscopic examination of lower respiratory tract secretions
were compared with histopathologic examination and
quantitative culture of lung tissue obtained from the same
area of the lung from which samples of secretions were taken
(14). These investigators observed 70% specificity and 65%
positive predictive value for bronchoscopically guided PSB
and 63% sensitivity and 79% negative predictive value for
bronchoscopically guided BAL. These patients were on
mechanical ventilation for a mean of 14 days and a median of
8 days and could have acquired one or more episodes of
pneumonia at any time while on mechanical ventilation. In
addition, 38 of 39 patients received antibacterial or
antifungal therapy in the 48 hours before death. However,
duration of therapy or change of antimicrobial therapy in the
72 hours before death was not stated. If antimicrobial therapy
had been changed, bacteria susceptible to the newly
instituted antimicrobial agents might not have been
recovered on culture of respiratory secretions and lung tissue
of patients who had histopathologic evidence of pneumonia.
In another study, the results of quantitative culture and
microscopic examination of lower respiratory tract secretions
were compared with histopathologic examination and
quantitative culture of simultaneously obtained lung tissue
in 25 patients on mechanical ventilation immediately after
death (15). Whether patients on antibiotic therapy at the time
of death had any changes in therapy in the 72 hours before
death or whether they had earlier episodes of VAP before the
episode of pneumonia diagnosed at the time of death was not
stated. In addition, these workers used >103 CFU/g of tissue
rather than >104 CFU/g as the threshold for positive lung
cultures, which may account for the lower sensitivity,
specificity, and positive and negative predictive values for
quantitative culture of secretions obtained by
bronchoscopically directed PSB and BAL.
Nonbronchoscopically Directed
(Blind) Diagnostic Techniques
Because of the invasive nature and cost of bronchoscopy,
investigators have evaluated other techniques for collecting
lower respiratory tract secretions. These nonbronchoscopic
techniques involve passage of a catheter or telescoping
catheters through the endotracheal tube with advancement to
a wedged position in the lung. Samples may be taken by
telescoping catheters containing a brush (blind PSB) (16-18),
aspiration of secretions into a distally wedged catheter
(19,20), or BAL through a distally wedged catheter (21-24).
BAL may be performed by using a balloon-tipped catheter
with the balloon inflated after the catheter has been advanced
to the wedged position (protected BAL) (21), by using
telescoping catheters (22,24), or by placing a catheter into the
wedged position with a guide wire (23).
Although nonbronchoscopic or blind techniques for
obtaining lower respiratory tract secretions appear promis-
ing, additional validation studies are needed before these
techniques are widely adopted and can be used in place of
bronchoscopically directed sampling techniques. Studies of
nonbronchoscopic sampling techniques have recently been
reviewed (25). Another indication of the need for further study
of the nonbronchoscopic sampling techniques is the absence of
Table. Quantitative cultures and microscopy examination of lower




techniques Sensitivity Specificity       value    value
PSBb cultures 82% 89% 90% 89%
  (>103 CFU/mL)
BAL cultures 91% 78% 83% 87%
  (>104 CFU/mL)
Microscopic 91% 89% 91% 89%
  examination of
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standardized diagnostic thresholds for quantitative culture of
lower respiratory tract specimens obtained by these
techniques.
Quantitative Cultures To Predict VAP Onset and
Monitor Therapy
To predict the onset of VAP in patients with adult
respiratory distress syndrome (ARDS), Delclaux et al. used
quantitative culture of lower respiratory tract secretions
obtained blindly by passing a plugged telescopic catheter
through the endotracheal tube (26). They observed that in 16
of 18 patients lower respiratory tract colonization (<103 CFU/
mL) evolved to pneumonia within 2 to 6 days. Colonizing
microorganisms were the same as those that caused
subsequent pneumonia. The 89% positive predictive value of
lower respiratory tract colonization for pneumonia further
substantiates the accuracy of quantitative culture of lower
respiratory tract secretions for the diagnosis of VAP.
Quantitative culture of lower respiratory tract secretions
can also be used to monitor the progress of antimicrobial
therapy for VAP. Montravers and co-workers diagnosed VAP
in 76 patients by using quantitative culture of lower
respiratory tract secretions obtained through bronchoscopically
directed PSB and recovered 135 isolates at >103 CFU/mL (27).
When a second PSB was performed by bronchoscopy 3 days
after start of therapy, 126 (93%) of the initial 135 isolates
were not recovered by the second PSB, 7 (5.2%) were recovered
at <103 CFU/mL, and 2 (1.5%) were still present at >103 CFU/
mL. The last two isolates were the only bacteria resistant to
initial treatment because of errors in selection of antibiotics.
Thus, results of quantitative cultures of respiratory
secretions obtained by repeat PSB were consistent with the
antimicrobial susceptibilities of isolates obtained by the first
PSB. The authors noted that when follow-up PSB cultures
were negative, the patients’ conditions improved. This study
further supports the accuracy of quantitative culture of lower
respiratory tract secretions for the diagnosis of VAP.
Repeatability of PSB and BAL
Repeatability, which is defined as the variation in
repeated measurements of the same quantity (28), is one
measure of the accuracy of a technique in diagnosing the
diseases(s) for which it was developed. Marquette and
associates performed a study in which a single investigator
performed bronchoscopy on 22 patients with suspected VAP
(28). At each bronchoscopy, five successive PSB samples were
taken from the same area of the lung. All PSB specimens were
cultured quantitatively by the same technologist. In each
patient, all five PSB procedures identified exactly the same
microorganisms. In 59% of the patients, there was more than
a 1-log variation in quantitative culture of the five PSB
specimens; in 3 (13.6%) of the 22 patients, quantitative
culture results were spread out on both sides of the 103 CFU/
mL breakpoint. Thus, in spite of the substantial variability of
the quantitative cultures, all five PSB procedures for 19
(86.4%) of 22 patients gave results on the same side of the
breakpoint, indicating acceptable repeatability.
The repeatability of BAL was assessed in a study in which
two BALs were performed in the same lobe 30 minutes apart
in 44 patients (29). The bronchoscope was sterilized between
procedures in each patient. The investigators observed that
both BALs yielded negative results in 28 patients and that the
same microorganism was recovered from both BALs in 14 of
16 patients. Thus, 40 of 44 pairs of BAL samples yielded the
same results, for a repeatability of 90.9%. Results of duplicate
BALs for 4 (25%) of the 16 patients with positive cultures were
spread out on both sides of the 104 CFU/mL diagnostic
threshold. Overall, BAL appears to have an acceptable (75%)
level of repeatability in patients with positive cultures.
Additional studies of the repeatability of PSB and BAL are
needed.
Antibiotics and Diagnosis of VAP by Quantitative
Culture of Lower Respiratory Tract Secretions
When patients with pneumonia are receiving antimicro-
bial agents at the time lower respiratory tract secretions are
obtained for diagnosis of VAP, cultures may be negative, and
concentrations of bacteria may be below the diagnostic
threshold. Such uncertainty about the interpretation of
culture results from patients on antibiotics has prompted
study of the effect of antibiotics on the diagnosis of VAP.
Timsit and co-workers assessed the impact of antimicrobial
therapy on the diagnosis of VAP by collecting lower
respiratory tract secretions by bronchoscopically directed
PSB and BAL from patients with suspected VAP (30). Ninety-
six patients had not received antimicrobial agents for >3 days
before bronchoscopy, while 65 patients had been on
antibiotics for >3 days at the time PSB and BAL samples were
obtained. Sensitivity and specificity did not differ for PSB,
BAL, and percentage of intracellular organisms in patients
receiving and not receiving antibiotics. The authors concluded
that when patients acquire pneumonia while on antibiotics
for infections at extrapulmonary sites, the microorganisms
are resistant to these antibiotics and the diagnostic yields of
PSB and BAL are unaffected.
Souweine et al. (31) confirmed and extended the
observations of Timsit and co-workers. In 63 episodes of
suspected VAP, 12 patients had received no antibiotics in the
4 days before bronchoscopy, 31 had been treated with
antibiotics for >72 hours, and 20 had begun antibiotics or had
their antibiotic regimen modified within the 24 hours before
bronchoscopy. The diagnosis of VAP was made by
bronchoscopically directed PSB, BAL, and microscopic
examination for intracellular organisms. The sensitivity for
the diagnosis of VAP by percentage of intracellular organisms
did not differ in the three groups. Nor did the sensitivity of
PSB and BAL differ in the group not receiving antibiotics and
the group receiving antibiotics for >72 hours. In the group of
patients with initiation or change of antibiotics in the 24
hours before bronchoscopy, the sensitivity of PSB and BAL
decreased substantially but was restored by reducing the
threshold for PSB to 102 CFU/mL and for BAL to 103 CFU/mL.
These studies suggest that the sensitivity of PSB and BAL for
the diagnosis of VAP is unchanged in patients who acquire
VAP while on antibiotics for >72 hours for treatment of an
extrapulmonary infection. Therefore, for such patients lower
respiratory tract secretions should be obtained for
quantitative culture and microscopic examination before any
changes are made in antimicrobial therapy.
Diagnosis of VAP in Patients with ARDS
VAP is more common in patients with ARDS than in
those with other causes of respiratory failure (26,32,33); it
occurs later and is caused by more resistant microorganisms.
The diagnosis of VAP is more difficult in such patients
because ARDS and VAP have very similar clinical203 Vol. 7, No. 2, March–April 2001 Emerging Infectious Diseases
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manifestations. Chastre et al. observed no significant
differences in temperature, leukocyte count, Pao2/Fio2 ratio,
or radiologic score in patients with ARDS with and without
VAP (32). Since clinical criteria for VAP lack both sensitivity
and specificity in patients with ARDS, microbiologic data are
thought to play a prominent role in the diagnosis of VAP that
complicates ARDS (26). In a study of the use of
bronchoscopically directed BAL to diagnose VAP in patients
with ARDS, bronchoscopic findings modified antibiotic
therapy in 91% of patients with positive BAL cultures and
prevented the use of new antibiotics in 54% of patients with
insignificant growth (33). Given the severity of illness of
patients with ARDS, particularly when complicated by VAP,
and the great difficulty in differentiating VAP from ARDS on
clinical and radiographic grounds, the most effective
approach to diagnosis of VAP in patients with ARDS is
quantitative culture and microscopic examination of lower
respiratory tract secretions.
Data Quality in the Diagnosis of VAP
Quantitative culture and microscopic examination of
lower respiratory tract secretions are most effective when
attention is paid to the quality of specimens from the lower
respiratory tract (8,34,35). The following practices are
recommended: 1) Antibiotics should not be started or changed
until after lower respiratory tract secretions have been
obtained. 2) When bronchoscopically directed techniques are
used, secretions should not be suctioned nor anesthetic
injected through the working channel of the bronchoscope. 3)
Less than 10% return of instilled fluid during BAL probably
represents inadequate sampling of the lower respiratory
tract. 4) When lower respiratory tract sampling is performed
by PSB, the brush must be placed into exactly 1 mL of fluid. 5)
Specimens should be delivered immediately to the laboratory.
6) Fewer than 10 cells per field at a magnification of 500x in
fluid obtained by PSB probably represents an inadequate
sample; resampling should be considered. 7) The presence of
>1% epithelial cells indicates an unreliable sample;
additional samples should be obtained.
In conclusion, in the absence of gold standard criteria for
the diagnosis of VAP, the diagnostic test of choice is
quantitative culture and microscopic examination of lower
respiratory tract secretions. This approach provides the most
accurate diagnosis of VAP and identification of the causative
microorganism(s), can predict the onset of VAP and provide
the identity and susceptibility of the causative
microorganism(s) at the time clinical manifestations of VAP
appear, can be used to assess the cause of therapy failure,
provides the most effective modality for diagnosis of VAP that
complicates ARDS, minimizes misclassification of cases of
VAP for studies on the epidemiology of VAP, and minimizes
the selective pressure for development of resistant
microorganisms. Whether this approach to the diagnosis of
VAP has an effect on outcome and reduces deaths is yet to be
determined.
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